Cover Image

Editorial: The unquenchable thirst for drinks and diets as treatments for constipation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yoav Mazor, Allison Malcolm
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Sonographic assessment of colonic content—A new tool for constipation?
by: Giovanni Maconi, et al.
Published: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
by: R. M. Mathias, et al.
Published: (2024)

Editorial: Vibrating capsule for severe chronic idiopathic constipation—Severity lies in the eye of the beholder
by: Sanskriti Varma, et al.
Published: (2024)

Testing in functional constipation—What's new and what works
by: Leonel Rodriguez
Published: (2024)

Meta‐analysis: Intestinal ultrasound to evaluate colonic contents and constipation
by: R. M. Mathias, et al.
Published: (2024)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
by: Daniel Tassone, et al.
Published: (2024)

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis
by: Dominik Bettinger, et al.
Published: (2024)

Editorial: Have you asked your patients about their difficulties in paying the medical costs of their treatment?
by: Abergel Armand, et al.
Published: (2024)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
by: Jakob B. Seidelin
Published: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
by: Yong‐Hai Zhou, et al.
Published: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
by: Jiamei Wang, et al.
Published: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
by: Tsz Hong Yiu, et al.
Published: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
by: Chen‐Pi Li, et al.
Published: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
by: Jian Wang, et al.
Published: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
by: Maria Ling Lundström, et al.
Published: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
by: Hyeyeon Hong, et al.
Published: (2024)

Editorial: Quantity is important!
by: Chee‐Kiat Tan
Published: (2024)

Editorial: Plants against animals
by: Einar S. Björnsson
Published: (2024)

Editorial: Terlipressin Induced Bradycardia
by: Nancy Reau, et al.
Published: (2025)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
by: Jing Li, et al.
Published: (2024)

Editorial: Quantity is important! Authors' reply
by: Marika Rudler, et al.
Published: (2024)

Editorial: Another brick in the CDST wall
by: Aurelien Amiot, et al.
Published: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
by: Manjeet Kumar Goyal, et al.
Published: (2026)

Editorial: Getting to the Heart of the Matter in IBD
by: Ashwin N. Ananthakrishnan
Published: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
by: Nobuharu Tamaki, et al.
Published: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
by: Maryam Alahmad, et al.
Published: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
by: WenXian OuYang, et al.
Published: (2024)

Editorial: Gastrointestinal symptoms—A world of differences
by: Kevin W. Olden
Published: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
by: Jeli Mendoza, et al.
Published: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
by: C. Stephens
Published: (2024)

Editorial: To Stop Or Not To Stop: Is It Still A Question?
by: Stephan R. Vavricka, et al.
Published: (2024)

Editorial: Defining corticosteroid use in clinical trials
by: J. Siffledeen
Published: (2024)

Editorial: Cardiometabolic criteria matters inMASLD
by: Margaret L. P. Teng, et al.
Published: (2024)

Editorial: Striving for Equitable Care in Ulcerative Colitis
by: Edward L. Barnes
Published: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
by: Mark C. C. Cheah, et al.
Published: (2025)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
by: Yu Liu, et al.
Published: (2024)

Editorial: The future of managing drug induced liver injury
by: Amanda Nicoll
Published: (2024)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
by: Maryam Zafer, et al.
Published: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
by: Kyuwon Kim, et al.
Published: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
by: Matthew D. Coates, et al.
Published: (2025)